Cough
Conditions
Keywords
Subacute Cough, selective P2X3 antagonist
Brief summary
The purpose of the study is to Evaluate the Efficacy and Safety of QR052107B 100mg， QR052107B 400mg in Patients with Subacute Cough.
Detailed description
This study adopted a multicenter, randomized, parallel-group, double-blind and placebo-controlled design, and it was planned to enroll 270 patients with subacute cough following respiratory tract infection. After a screening period of 1-4 days, eligible subjects were randomized to the QR052107B 100 mg QD group, QR052107B 400 mg QD group and placebo group at a ratio of 1:1:1. The efficacy of QR052107B Tablets in the treatment of subacute cough was evaluated after 9 consecutive days of dosing. This study is divided into 3 stages: screening period, administration and observation period, and safety follow-up period.
Interventions
DRUGQR052107B 100 mg
QR052107B 100 mg QD
DRUGQR052107B 400 mg
QR052107B 400 mg QD
DRUGPlacebo
placebo QD
Sponsors
Wuhan Createrna Science and Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The treatment assignment during the the administration and observation period will be kept blinded to participants, investigators, care providers, and outcome assessors if applicable.
Intervention model description
Eligible subjects were randomized at a ratio of 1:1:1 into QR052107B 100 mg QD, QR052107B 400 mg QD and placebo groups and then entered the administration and observation period.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Aged 18-75 (both inclusive), male or female. 2. Subjects with 18 kg/m2 ≤ BMI ≤ 30 kg/m2 at screening. 3. Subjects who have been diagnosed by the investigator with subacute cough (course of disease: 3-8 weeks) following respiratory tract infection. 4. Subjects who are willing to discontinue previous antitussives at screening. 5. Subjects who are willing to discontinue traditional Chinese medicines or Chinese patent medicines at screening. 6. Agreement to use at least one effective method of contraception during the study and for 3 months after the final dose. 7. Subjects who agree not to donate any sperm or egg during the study and for 3 months after the final dose. 8. Subjects who agree to sign the ICF and comply with all aspects of the study.
Exclusion criteria
1. Subjects with SPO2 ≤ 93% or significant polypnoea at rest during screening. 2. Subjects who have undergone chest X-ray or CT within 2 weeks before screening and have clinically significant lung lesions as judged by the investigator. 3. Subjects with cough and a large amount of thick phlegm that is difficult to expectorate and facing more safety risks in this study as judged by the investigator. 4. Subjects with acute respiratory tract infection (such as sputum purulent, pyrexia, white blood cell count increased or neutrophil count increased, and hs-CRP increased) as judged by the investigator at screening. 5. Subjects with infection in systems other than the respiratory system requiring systemic anti-infective therapy as judged by the investigator at screening. 6. Subjects with a history of chronic sinusitis, rhinitis allergic, seasonal cough and cough variant asthma (CVA), or with a history of systemic skin/mucosa allergy within 8 weeks before screening. 7. Subjects with a clear history of lung disorders (such as bronchial asthma, chronic obstructive pulmonary disease, pneumonia interstitial, pulmonary carcinoma and bronchiectasis) and unsuitable for this clinical study as judged by the investigator. 8. Subjects with severe or poorly controlled pre-existing diseases of various systems other than the respiratory system (such as liver disorders, chronic kidney disease, severe hematological diseases, chronic cardiac failure congestive \[New York Heart Association (NYHA) Class III/IV\], acute coronary syndrome, nervous system disorders including cerebrovascular and neuromuscular diseases, and metabolic diseases) and unsuitable for this clinical study as judged by the investigator. 9. Subjects with clinically significant abnormalities in clinical laboratory tests at screening and unsuitable for this clinical study as judged by the investigator, including but not limited to the following: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), serum total bilirubin (TBIL), and creatinine (Cr) \> 200% × upper limit of normal (ULN). 10. History of alcohol or drug abuse in the past year. 11. Past or current history of major mental disorders. 12. Female subjects who are pregnant or lactating. 13. Subjects who are current smokers or have quit smoking within 6 months before screening. 14. Subjects who have participated in any other clinical trial within 3 months prior to screening, or are still in the safety washout period (\< 5 half-lives) of the previous clinical trial on the first dosing day in this study, whichever is longer. 15. Presence of other factors that may increase the risk to subjects, affect the study results, or interfere with their participation in the whole study process, including but not limited to abnormal vital signs, physical examinations, ECGs and/or clinical laboratory tests, as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GMR of mean coughs per hour within 24 hours on D10 versus baseline | Baseline and day 10 | The geometric mean ratio (GMR) of mean coughs per hour within 24 hours on day10 versus baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMR of mean coughs per hour within 24 h on D4 versus baseline in patients of ≥ 20 coughs per hour within 24 h at baseline | Baseline and day 4 | The geometric mean ratio of mean coughs per hour within 24 hours on day 4 versus baseline in patients of ≥ 20 coughs per hour within 24 h at baseline. |
| GMR of mean coughs per hour within 24 hours on D4 versus baseline | Baseline and day 4 | The geometric mean ratio of mean coughs per hour within 24 hours on day 4 versus baseline. |
| GMR of mean awake coughs per hour on D10 versus baseline | Baseline and day 10 | The geometric mean ratio of mean awake coughs per hour on day 10 versus baseline. |
| GMR of mean coughs per hour within 24 h on D10 versus baseline in patients of ≥ 20 coughs per hour within 24 h at baseline | Baseline and day 10 | The geometric mean ratio of mean coughs per hour within 24 hours on day10 versus baseline in patients of ≥ 20 coughs per hour within 24 h at baseline. |
| Change from baseline in cough severity VAS score on D4 and D10 | Baseline, day 4 and day10 | The changes in cough severity VAS score on D4 and D10 relative to baseline. |
| Change from baseline in LCQ-acute score on D4 and D10 | Baseline, day 4 and day10 | The changes in LCQ-acute score on D4 and D10 relative to baseline. |
| Change from baseline in sleep VAS score on D4 and D10 | Baseline, day 4 and day10 | The changes in sleep VAS score on D4 and D10 relative to baseline. |
| GMR of mean awake coughs per hour on D4 versus baseline | Baseline and day 4 | The geometric mean ratio of mean awake coughs per hour on day 4 versus baseline. |
Countries
China
Outcome results
None listed